CJC-1295 and Ipamorelin Stack: Complete Dosing Protocol

The combination of CJC-1295 and Ipamorelin represents one of the most extensively studied peptide stacks in growth hormone research. This synergistic pairing has attracted significant attention due to the complementary mechanisms through which these peptides influence the growth hormone axis. This comprehensive protocol provides detailed information on dosing, administration timing, reconstitution procedures, and research considerations for this peptide combination.

Understanding the CJC-1295 and Ipamorelin Combination

The rationale for combining CJC-1295 and Ipamorelin stems from their distinct but complementary mechanisms of action within the growth hormone regulatory system. CJC-1295, a growth hormone-releasing hormone (GHRH) analog, works by stimulating the pituitary gland to produce and release growth hormone. Meanwhile, Ipamorelin functions as a growth hormone secretagogue receptor (GHSR) agonist, mimicking the action of ghrelin to promote growth hormone release through a separate pathway.

This dual-pathway approach offers theoretical advantages over single-peptide protocols. When GHRH analogs and GHSR agonists are used together, research suggests a synergistic effect that produces growth hormone elevations greater than the sum of each peptide's individual effect. This synergy occurs because the two peptides work through different mechanisms that complement rather than compete with each other.

CJC-1295 exists in two primary forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (often called Modified GRF 1-29). The version with DAC features an extended half-life of approximately 6-8 days, while the version without DAC has a much shorter half-life of approximately 30 minutes. The choice between these variants significantly impacts dosing protocols and administration schedules.

Ipamorelin maintains a relatively short half-life of approximately 2 hours, which necessitates multiple daily administrations for sustained effect in most research protocols. Its selectivity for growth hormone release, with minimal impact on cortisol and prolactin levels, makes it particularly valuable for combination protocols.

Standard Dosing Protocols

CJC-1295 with DAC and Ipamorelin Protocol

When utilizing CJC-1295 with DAC, the extended half-life allows for less frequent administration compared to the non-DAC variant. Research protocols typically employ the following parameters:

CJC-1295 with DAC:

• Dose range: 1-2 mg per administration
• Frequency: Once or twice weekly
• Common schedule: Every 3.5 days (twice weekly) or weekly
• Total weekly dose: 2-4 mg

Ipamorelin (when stacked with CJC-1295 with DAC):

• Dose range: 200-300 mcg per administration
• Frequency: 1-3 times daily
• Common schedule: Before bed, or before bed and upon waking
• Total daily dose: 200-900 mcg

The rationale for this protocol recognizes that CJC-1295 with DAC provides sustained GHRH activity throughout the week, while Ipamorelin administrations create pulsatile growth hormone release on top of this baseline enhancement. This mimics the body's natural pulsatile growth hormone secretion pattern while maintaining elevated baseline activity.

CJC-1295 without DAC (Modified GRF 1-29) and Ipamorelin Protocol

The shorter half-life of CJC-1295 without DAC necessitates more frequent administration but allows for greater control over timing and pulsatility:

CJC-1295 without DAC:

• Dose range: 100-200 mcg per administration
• Frequency: 1-3 times daily
• Common schedule: Upon waking, post-workout, before bed
• Total daily dose: 100-600 mcg

Ipamorelin (when stacked with CJC-1295 without DAC):

• Dose range: 100-300 mcg per administration
• Frequency: 1-3 times daily (administered simultaneously with CJC-1295)
• Common schedule: Upon waking, post-workout, before bed
• Total daily dose: 100-900 mcg

This protocol involves administering both peptides together at the same time points throughout the day. The simultaneous administration capitalizes on the immediate synergistic effect, creating distinct pulses of growth hormone release that more closely mimic natural physiology.

Reconstitution and Preparation Guidelines

Proper reconstitution is critical for maintaining peptide stability and ensuring accurate dosing. Both CJC-1295 and Ipamorelin arrive as lyophilized (freeze-dried) powders that require reconstitution with bacteriostatic water before administration.

Reconstitution Process

Materials needed:

• Lyophilized peptide vial(s)
• Bacteriostatic water (0.9% benzyl alcohol)
• Alcohol swabs
• Appropriate syringes (typically insulin syringes)

Step-by-step procedure:

1. Preparation: Allow refrigerated peptides to reach room temperature (approximately 15-20 minutes). This prevents condensation and ensures accurate reconstitution.

2. Sterilization: Clean the rubber stoppers of both the peptide vial and bacteriostatic water vial with alcohol swabs. Allow to air dry for 30 seconds.

3. Draw bacteriostatic water: Using a sterile syringe, draw the desired amount of bacteriostatic water. Common dilution ratios include:

   • 2 mg peptide + 2 mL bacteriostatic water = 1 mg/mL concentration
   • 5 mg peptide + 2.5 mL bacteriostatic water = 2 mg/mL concentration

4. Inject water: Slowly inject the bacteriostatic water into the peptide vial. Direct the stream along the inside wall of the vial rather than directly onto the peptide powder to minimize degradation from mechanical force.

5. Gentle mixing: Do not shake the vial. Instead, gently swirl or roll the vial between your palms until the powder fully dissolves. This typically takes 1-3 minutes. The solution should be clear without visible particles.

6. Storage: Once reconstituted, immediately refrigerate at 2-8°C (36-46°F). Reconstituted peptides typically remain stable for 30-60 days when properly stored.

Dosing Calculations

Accurate dosing requires understanding concentration calculations. Using an example with CJC-1295:

If you reconstitute 2 mg of CJC-1295 with 2 mL of bacteriostatic water:

• Concentration = 2 mg / 2 mL = 1 mg/mL = 1000 mcg/mL

For a 100 mcg dose:

• Volume needed = 100 mcg / 1000 mcg/mL = 0.1 mL = 10 units on insulin syringe

For Ipamorelin at 5 mg reconstituted with 2.5 mL:

• Concentration = 5 mg / 2.5 mL = 2 mg/mL = 2000 mcg/mL

For a 200 mcg dose:

• Volume needed = 200 mcg / 2000 mcg/mL = 0.1 mL = 10 units on insulin syringe

Administration Timing Strategies

The timing of peptide administration significantly influences research outcomes due to the interaction with endogenous growth hormone secretion patterns, feeding status, and circadian rhythms.

Optimal Administration Times

Morning administration (upon waking): Research protocols frequently include a morning dose because natural growth hormone secretion is relatively low during early waking hours following the nighttime pulse. Administering peptides at this time on an empty stomach (having fasted overnight) maximizes growth hormone response. Research subjects should ideally wait 15-30 minutes before consuming food to avoid blunting the growth hormone response, as elevated glucose and insulin can suppress growth hormone release.

Post-exercise administration: The post-exercise window represents another strategic timing opportunity. Exercise itself stimulates growth hormone release, and administering growth hormone secretagogues in the post-exercise period may amplify this natural response. Optimal timing appears to be immediately post-workout or within 30 minutes. This window also typically coincides with lower blood glucose levels (depending on pre-workout nutrition), which favors growth hormone secretion.

Bedtime administration: The largest natural pulse of growth hormone occurs during deep sleep, typically 60-90 minutes after sleep onset. Administering peptides 30-60 minutes before bed aims to enhance this natural nighttime pulse. This timing strategy is particularly common in protocols using once-daily or twice-daily administration schedules.

Multi-Dose Daily Schedules

For protocols using CJC-1295 without DAC and Ipamorelin three times daily, a typical schedule might include:

Schedule A: Maximum frequency

• 6:00 AM - Upon waking (fasted state)
• 4:00 PM - Post-workout or mid-afternoon
• 10:00 PM - Before bed

Schedule B: Conservative approach

• 6:00 AM - Upon waking (fasted state)
• 10:00 PM - Before bed

Schedule C: Performance-focused

• 4:00 PM - Pre-workout
• 10:00 PM - Before bed

The choice of schedule depends on research objectives, with higher frequency potentially producing more sustained elevation of IGF-1 levels and more consistent growth hormone pulsatility.

Advanced Protocol Considerations

Saturation Dosing

Some research protocols implement a saturation or loading phase during the initial 1-2 weeks. This approach uses higher doses to rapidly achieve steady-state peptide concentrations and maximize initial IGF-1 elevation. A saturation protocol might include:

Week 1-2 (CJC-1295 without DAC + Ipamorelin):

• CJC-1295: 200 mcg three times daily
• Ipamorelin: 300 mcg three times daily

Week 3 onwards (maintenance):

• CJC-1295: 100 mcg twice daily
• Ipamorelin: 200 mcg twice daily

However, evidence for superiority of saturation dosing compared to consistent dosing remains limited in published research.

Cycling Strategies

Peptide desensitization represents a theoretical concern with continuous long-term use, though actual clinical evidence for growth hormone secretagogue receptor desensitization with Ipamorelin is minimal. Nonetheless, some research protocols incorporate cycling strategies:

Continuous protocol:

• Daily administration without breaks for 3-6 months

5-days-on/2-days-off protocol:

• Administration Monday through Friday
• Weekend break
• Theoretical benefit: Prevents receptor desensitization while maintaining elevated baseline IGF-1

8-weeks-on/4-weeks-off protocol:

• Continuous administration for 8 weeks
• Complete cessation for 4 weeks
• Resume for another 8-week cycle

Current research does not definitively establish the necessity of cycling for these specific peptides, and continuous protocols are commonly employed without apparent loss of efficacy.

Dose Escalation Approach

Conservative protocols may implement gradual dose escalation to assess tolerance and response:

Week 1-2:

• CJC-1295: 50-100 mcg per dose
• Ipamorelin: 100-150 mcg per dose
• Frequency: Once or twice daily

Week 3-4:

• CJC-1295: 100-150 mcg per dose
• Ipamorelin: 150-200 mcg per dose
• Frequency: Twice daily

Week 5 onwards:

• CJC-1295: 100-200 mcg per dose
• Ipamorelin: 200-300 mcg per dose
• Frequency: 2-3 times daily

This approach allows for monitoring of any adverse responses while progressively optimizing the dose based on observed effects.

Administration Route and Technique

Both CJC-1295 and Ipamorelin are administered via subcutaneous injection in research protocols. Proper injection technique is essential for consistent peptide delivery and minimizing tissue reactions.

Injection Sites

Common subcutaneous injection sites include:

Abdominal region: The most frequently used site, typically 2-3 inches from the navel, avoiding the midline. This area provides consistent absorption and ample subcutaneous tissue.

Thigh: The outer front portion of the thigh, approximately midway between hip and knee.

Deltoid area: The fatty tissue overlying the deltoid muscle in the upper arm (requires assistance or flexibility).

Gluteal region: The upper outer quadrant of the buttocks (though less convenient for self-administration).

Site rotation is recommended to prevent lipohypertrophy or lipoatrophy from repeated injections in the same location. A systematic rotation pattern ensures at least 72 hours between injections at the same site.

Injection Procedure

1. Hand washing: Thoroughly wash hands with soap and water.

2. Site preparation: Clean the chosen injection site with an alcohol swab in a circular motion, working outward from the center. Allow to air dry.

3. Pinch technique: Gently pinch the skin to create a raised area of subcutaneous tissue, ensuring the needle will not reach muscle.

4. Needle insertion: Hold the syringe like a dart at a 45-90 degree angle (depending on needle length and subcutaneous fat thickness). Insert the needle smoothly in a single motion.

5. Aspiration (optional): Some protocols recommend gentle aspiration to ensure the needle is not in a blood vessel, though this is controversial for subcutaneous injections.

6. Injection: Slowly depress the plunger over 3-5 seconds to inject the solution.

7. Withdrawal: Remove the needle at the same angle of insertion and apply gentle pressure with a clean alcohol swab if needed.

8. Disposal: Immediately dispose of used needles in an appropriate sharps container.

Monitoring and Assessment Parameters

Comprehensive research protocols incorporate various monitoring parameters to assess the effects of CJC-1295 and Ipamorelin combination therapy.

Baseline and Periodic Laboratory Assessments

Before protocol initiation:

• IGF-1 (Insulin-like Growth Factor 1) levels
• Complete metabolic panel (glucose, liver enzymes, kidney function)
• Lipid panel
• Complete blood count
• HbA1c (glycated hemoglobin)
• Thyroid function (TSH, free T3, free T4)

Periodic monitoring (every 4-8 weeks):

• IGF-1 levels (primary marker of growth hormone activity)
• Fasting glucose and HbA1c (monitor glucose metabolism)
• Liver function tests (ALT, AST)

IGF-1 levels typically show elevation within 2-4 weeks of consistent peptide administration, with peak levels often achieved by 6-8 weeks. Monitoring IGF-1 helps assess protocol effectiveness and guides dose adjustments.

Subjective Assessment Markers

Beyond laboratory values, research protocols often track subjective parameters:

• Sleep quality and duration
• Recovery time between exercise sessions
• Body composition changes (via DEXA scan, bioimpedance, or measurements)
• Energy levels and fatigue
• Skin quality and appearance
• Injury healing rates
• Joint comfort and mobility

These parameters, while subjective, provide valuable context for assessing the overall research outcomes.

Safety Considerations and Contraindications

While CJC-1295 and Ipamorelin demonstrate favorable safety profiles in research settings, certain considerations warrant attention.

Common Side Effects

Research has documented several potential side effects:

Injection-site reactions: Mild redness, swelling, or itching at injection sites, typically resolving within 24-48 hours. Proper injection technique and site rotation minimize these reactions.

Head rush or flushing: Some subjects report a brief sensation of warmth or head rush within minutes of injection, typically lasting 5-15 minutes. This appears more common with higher Ipamorelin doses.

Water retention: Transient fluid retention may occur, particularly during initial